Real-world efficacy of postoperative adjuvant EGFR-TKI therapy for stage IA2-IA3 lung adenocarcinoma with high-risk pathological factors
Generally, postoperative EGFR-TKI therapy might provide no significant clinical benefits for stage IA2-IA3 lung adenocarcinoma patients with high-risk pathological factors. However, in specific subgroup, such as patients receiving lobectomy, EGFR-TKI therapy shows potential benefit which requires further exploration in the future.
Authors
- Shan Lu (ORCID: https://orcid.org/0000-0002-8262-8779)
- Zhuangzhuang Cong
- Chenxu Liu (ORCID: https://orcid.org/0000-0002-0370-0294)
- Peng Zhao (ORCID: https://orcid.org/0000-0001-5208-5809)
- Shen Yi
- Heng Tao
- Jing Luo (ORCID: https://orcid.org/0009-0008-3540-4191)
Institutions
- Nanjing University of Chinese Medicine (CN)
- Nanjing General Hospital of Nanjing Military Command (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1186/s12957-025-04065-w
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China